

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration or for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, C. or PLC.

Registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed



Dated 25 July 2006

# Request for grant of a patent

(See the notes on the back of this form. You can also get  
an explanatory leaflet from the Patent Office to help  
you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference **21 AUG 2002** **GMW/RAC/P19585GB** **00389/G6**

2. Patent application number **0219512.1** **21 AUG 2002**  
(The Patent Office will fill in this)

3. Full name, address and postcode of the or of  
each applicant (underline all surnames)  
Norton Healthcare Limited  
Albert Basin  
Royal Docks  
London  
E16 2QJ  
United Kingdom

Patents ADP number (if you know it)

**6188221003**

If the applicant is a corporate body, give the  
country/state of its incorporation

United Kingdom

4. Title of the invention  
Inhalation Compositions With High Drug  
Ratios

5. Name of your agent (if you have one) **ELKINGTON AND FIFE**  
"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)  
**ELKINGTON AND FIFE**  
**PROSPECT HOUSE**  
**8 PEMBROKE ROAD**  
**SEVENOAKS**  
**KENT**  
**TN13 1XR**  
**Martin A. Hay**  
**13 Queen Victoria St**  
**Macclefield**  
**Cheshire**  
**SK11 6LP**

Patents ADP number (if you know it)

**67004**

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of Filing (day/month/year)
	N/A		

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of Filing (day/month/year)
	N/A	N/A

Patents Form 1/77

8. ☐ statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if:

Yes

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

-

Description

5

Claim(s)

12

Abstract

-

Drawing(s)

-

10. If you are also filing any of the following, state how many against each item.

Priority documents

-

Translations of priority documents

-

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

-

Request for preliminary examination and search (Patents Form 9/77)

-

Request for substantive examination (Patents Form 10/77)

-

Any other documents (please specify)

-

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

Elkington and Fife

Elkington and Fife

21 August 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr Gordon Wright  
01732 458881

## INHALATION COMPOSITIONS WITH HIGH DRUG RATIOS

This invention relates to dry powder inhalation compositions, their preparation and use. In particular, it is concerned with formulations of the medicament formoterol and pharmaceutically acceptable derivatives thereof mixed with particulate lactose.

In order to be able to be inspired into the key target sites in the lungs of patients, inhalation drugs are typically provided in micronized form with average particle sizes of up to 10 microns. A number of devices have been developed for assisting the delivery of such medicaments into the lungs of patients. In one sort of device, a dry powdered inhaler (DPI) device, the medicament to be inhaled is dispensed into an air stream produced by the inspiratory action of the patient. A large number of such devices have been developed. The device may be a single dose device (eg wherein drug is dispensed from a pre-metered dosage means such as a capsule) or multidose (where the drug is stored in a reservoir and then metered prior to dispersal in the air stream or where the drug is pre-metered and stored in multiple dosage packs such as blisters). In many (but not all) DPI devices, the particulate drug is mixed with an excipient powder of larger average particle size and the drug particles are blended with the excipient to create a generally homogenous mixture. The larger particle size of the excipient results in the powder mixture being flowable, and the homogeneity of the mixture enables it to be metered into accurately measurable doses. This is of particular importance when only very small quantities of the drug are required in a dose. Excipient powders of this kind, pharmaceutical powder compositions for inhalation utilising such excipients are described, for example, in US Patent 3 957 965.

The accurate metering of highly potent inhalable drugs causes particular problems, as the quantity of medicament in the composition relative to that of the carrier is likely to be particularly small. (Less than 1 part of drug to 50 parts of carrier). One such medicament is formoterol which is often administered to patients at a dose of less than 60 micrograms; doses may be as small as 6 micrograms. We have now found dry powder inhalation compositions of formoterol which can be accurately metered and at the same time give good dose uniformity when administered to patients, particularly when used in dry powder devices such as that described in WO 92/10229. In addition,

such compositions can give better dispersions when dispensed from such devices, then previously described compositions. Certain compositions may also be more stable.

5 According to the invention, we provide a dry powder inhalation composition comprising formoterol or a pharmaceutically acceptable derivative thereof as active ingredient and pharmaceutically acceptable particulate carrier, wherein the composition comprises at least 0.25% by weight of the active ingredient.

10 We prefer compositions which comprise less than 10% by weight of the active ingredient.

Preferred compositions comprise from 0.26 to 1% by weight of the active ingredient, more especially 0.265 to 0.5% by weight of the active ingredient.

15 Although a range of pharmaceutically acceptable particulate carriers are known for use in inhalation formulations, such as sugar, in particular di- and polysaccharides, we particularly prefer lactose, especially alpha lactose monohydrate.

20 In general, the particle size of the carrier should be such that it can be entrained in an air stream but not deposited in the key target sites of the lung. Accordingly, carrier, with volume median diameter (VMD) or mass median diameter (MMD) of less than 40 microns is generally excluded. We prefer the carrier, eg lactose, to have a VMD or MMD of from 50 to 250 $\mu$ m eg from 50 to 60 $\mu$ m or 60 to 90 $\mu$ m or 90 to 150 $\mu$ m.

25 The compositions of the present invention may be used in the treatment of chronic obstructive pulmonary disease.

30 The active ingredient may be in any isomeric form or mixture of isomeric forms, for example a pure enantiomer, particularly the R, R-enantiomer, a mixture of enantiomers, a race mate or a mixture thereof. Pharmaceutically acceptable derivatives of formoterol include pharmaceutically acceptable salts, in particular acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric or phosphoric acid. The salt may also be with an organic acid such as acetic, succinic, maleic,

furmaric, citric, tartaric, lactic or benzoic. The active ingredient and pharmaceutically acceptable derivatives thereof may exist in the form of a solvate, in particular a hydrate. A preferred form of active ingredient for use in the invention is formoterol fumarate, especially formoterol fumarate di-hydrate, conveniently in its racemic form.

5 Formoterol, salts and hydrates thereof and salt hydrates thereof as described above may be prepared by known methods, for example as described in US 3 994 974 or US 5 684 199.

10 In general, the active ingredient is present in the dry powder composition at an amount which is less than 10 %, preferably less than 2 % and most preferably less than 1 %. The actual amount of active ingredient in the composition will depend to a large extent on the nature of the dry powder inhaler and the quantity of composition that is metered individual dose. Where a large dose of composition is metered, the proportion of formoterol in the dose will be reduced. Particularly, dilute compositions are disclosed  
15 in WO 01/39745, for example 0.02 % by weight.

The mean particle diameter of the active ingredient is preferably up to 10 microns, more preferably up to 5 microns especially from 1 to 5 microns. The particle size of the active ingredient and of the carrier can be reduced to the desired level by  
20 conventional means, for example by grinding in a mill for example an air jet, ball or vibrator mill, by sieving, by spray-drying or by lyophilisation.

The dry powder composition may be metered and filled into capsules, eg gelatine or hydroxypropyl methol cellulose capsules such that the capsule contains a unit dose of  
25 active ingredient.

Doses of active ingredient to be held in accordance with the invention, may be in general from 1 to 60 micrograms. When the active ingredient is formoterol fumarate dihydrate, the dose may be, for example, from 6 to 54 micrograms. Preferred doses are  
30 from 6 to 24 micrograms, especially the unit doses of 6 micrograms, 12 micrograms and 24 micrograms. These doses may be administered once or twice daily.

When the dry powder is in a capsule containing a unit dose of active ingredient, the total amount of composition will depend on the size of the capsules and the characteristics of the inhalation device with which the capsules are being used. However, characteristic total fill weights of dry powder per capsule are between 1 and 5 mg.

Alternatively, the dry powder composition according to the invention may be filled into the reservoir of a multidose dry powder inhaler, for example of the kind illustrated in WO 92/10229.

Compositions according to the invention may be readily prepared by blending the required amount of active ingredient with the required amount of particulate carrier of the desired particle size distribution.

#### **Example 1**

0.265 grams of formoterol (as the fumarate dihydrate salt) was blended with 99.735 grams of lactose with VMD or MMD of 89-110 microns and a geometric standard deviation (GSD) of 2.2-4.9 and filled into the reservoir of a dry powder inhaler of the type illustrated in WO 92/10229.

The inhalers that contained the formulation were then tested for pharmaceutical performance under conditions specified in European Pharmacopoeia (2001). The drug per actuation (DPA) was measured using a dose unit sampling unit whilst fine particle dose (FPD) and fine particle fraction (FPF) were measured using a 5-stage liquid impinger

The compositions gave excellent dose uniformity when used in association with the device of WO 92/10229 which produced all mean doses within 80-120% label claim and overall relative standard deviation (RSD) < 15% (Table 1). The same products also result in over 40% drug particles having aerodynamic particle size < 5 microns,

suggesting that they are highly efficient in generating deeply inspirable drug . Typical in vitro deposition profiles are shown in Table 2.

Table 1. Dose consistency over life of IvaxIvax Formoterol MDPI, expressed as % label claim (LC)

<b>Strength</b>	<b>Overall mean in mcg (RSD)</b>	<b>% mean doses within 85-115% LC</b>	<b>% individual doses within 80-120% LC</b>	<b>% Individual doses within 75-125% LC</b>
6 mcg (n=930)	5.7 (13%)	95	93	96
12 mcg (n=500)	12.2(10%)	100	97	99

(n= number of doses. Ten doses from the beginning, middle and end of device life were collected from each inhaler).

**Table 2.** In vitro deposition profiles of formoterol from the IvaxIvax MDPI

<b>Strength</b>	<b>RD (<math>\mu</math>g)</b>	<b>FPD (<math>\mu</math>g)</b>	<b>FPF (% RD)</b>
6 mcg	5.0 - 5.9	2.4 - 2.8	48 - 48
12 mcg	11.1 - 13.4	5.4 - 7.2	49 - 54

RD - Recovered dose

FPD - Fine particle dose

FPF - Fine particle fraction

#### CLAIMS:

1. A dry powder inhalation composition comprising formoterol or a pharmaceutically acceptable derivative thereof as active ingredient and a pharmaceutically acceptable particulate carrier, wherein the composition comprises at least 0.25% by weight of the active ingredient.

2. A composition according to Claim 1, wherein the composition comprises less than 10% by weight of the active ingredient.



3. A composition according to Claim 1 or Claim 2, wherein the composition comprises from 0.26 to 1% by weight of the active ingredient.
4. A composition according to any one of the preceding Claims, which comprises
- 5 from 0.265 to 0.5% by weight of the active ingredient.
5. A composition according to any one of the preceding Claims, wherein the carrier is lactose.
- 10 6. A composition according to any one of the preceding Claims, wherein the particle size of the carrier is less than 250 microns.
7. A composition according to any one of the preceding Claims, wherein the particle size of the active ingredient is less than 10 microns.
- 15 8. A capsule containing from 1 to 25 mg of a composition according to any one of Claims 1 to 7
9. A multidose dry powder inhaler including a reservoir containing from 5 to 50
- 20 grams of a composition according to any one of Claims 1 to 7.